Press Release:

Mitsubishi Tanabe Pharma Corporation

Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation

Osaka, Japan, August 31, 2012--Mitsubishi Tanabe Pharma Corporation (President and Representative Director: Michihiro Tsuchiya; hereinafter, Mitsubishi Tanabe Pharma) has concluded an agreement with Nipro Corporation (Head Office: Osaka; President and Representative Director: Yoshihiko Sano; hereinafter, Nipro) regarding the dissolution of the joint venture between the two companies involving Bipha Corporation (Head Office: Chitose, President and Representative Director, Takehiko Fujii; hereinafter, Bipha). Under the terms of the agreement, Mitsubishi Tanabe Pharma will acquire all of the 20,580 shares of Bipha held by Nipro (49% of issued shares) and Bipha will become a wholly owned subsidiary of Mitsubishi Tanabe Pharma. The transfer of shares from Nipro to Mitsubishi Tanabe Pharma is planned for September 5, 2012.

Bipha was established in November 1996 as a wholly owned subsidiary of Mitsubishi Tanabe Pharma. In February 2001, Nipro (at that time, Nissho Corporation), acquired 49% of Bipha with the objective of facilitating rapid business progress and new application development in the field of recombinant human serum albumin preparations, which Bipha was developing. At that point, Mitsubishi Tanabe Pharma and Nipro commenced a joint venture.

Nipro reconsidered these operations and requested the dissolution of the joint venture. Mitsubishi Tanabe Pharma decided to acquire all of the Bipha shares held by Nipro and to manage these operations with Bipha as a wholly owned subsidiary.

This decision will contribute to the rapid restart of production and sales of Medway® INJECTION 25%, the recombinant human serum albumin preparation produced by Bipha and will help Japan to achieve national self-sufficiency in albumin preparations.

<Reference: Overview of Bipha Corporation>
1. Name: Bipha Corporation
2. Location: 1007–124, Izumisawa, Chitose City, Hokkaido
3. Representative: President & Representative Director, Takehiko Fujii
4. Lines of business: Pharmaceutical manufacturing, others
5. Date of establishment: November 1, 1996
6. Capital: ¥7.5 billion
7. Number of issued shares: 42,000 shares
8. Stockholders:
   Prior to stock transfer:
   Mitsubishi Tanabe Pharma: 21,420 shares (51%)
   Nipro: 20,580 shares (49%)

   After stock transfer:
   Mitsubishi Tanabe Pharma: 42,000 shares (100%)

<Contact for Inquiries>
Corporate Communications Department
Phone: +81-6-6205-5211